Cargando…

Cell Therapy in Idiopathic Pulmonary Fibrosis†

Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical stu...

Descripción completa

Detalles Bibliográficos
Autor principal: Serrano-Mollar, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164035/
https://www.ncbi.nlm.nih.gov/pubmed/30104544
http://dx.doi.org/10.3390/medsci6030064
_version_ 1783359504204693504
author Serrano-Mollar, Anna
author_facet Serrano-Mollar, Anna
author_sort Serrano-Mollar, Anna
collection PubMed
description Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical studies. In this review, the current knowledge of these cell therapies is summarized. Although further investigations are required, these studies indicate that cell therapies are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis.
format Online
Article
Text
id pubmed-6164035
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-61640352018-10-10 Cell Therapy in Idiopathic Pulmonary Fibrosis† Serrano-Mollar, Anna Med Sci (Basel) Review Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical studies. In this review, the current knowledge of these cell therapies is summarized. Although further investigations are required, these studies indicate that cell therapies are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis. MDPI 2018-08-13 /pmc/articles/PMC6164035/ /pubmed/30104544 http://dx.doi.org/10.3390/medsci6030064 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Serrano-Mollar, Anna
Cell Therapy in Idiopathic Pulmonary Fibrosis†
title Cell Therapy in Idiopathic Pulmonary Fibrosis†
title_full Cell Therapy in Idiopathic Pulmonary Fibrosis†
title_fullStr Cell Therapy in Idiopathic Pulmonary Fibrosis†
title_full_unstemmed Cell Therapy in Idiopathic Pulmonary Fibrosis†
title_short Cell Therapy in Idiopathic Pulmonary Fibrosis†
title_sort cell therapy in idiopathic pulmonary fibrosis†
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164035/
https://www.ncbi.nlm.nih.gov/pubmed/30104544
http://dx.doi.org/10.3390/medsci6030064
work_keys_str_mv AT serranomollaranna celltherapyinidiopathicpulmonaryfibrosis